Aptevo Therapeutics Inc
NASDAQ:APVO
Intrinsic Value
Aptevo Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on developing novel immunotherapies for the treatment of cancer. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of APVO.
Aptevo Therapeutics Inc's market capitalization is 459.7k USD.
APVO stock price is 0.6826 USD.
APVO.
APVO. Open DCF Valuation
APVO. Open Relative Valuation
APVO.
APVO's ROE (Return on Equity) has significantly increased in the last 3 years from -217% to -115%, and is approaching profitability.
APVO's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from -385% to -483%, and is approaching profitability.
APVO's long-term assets (25m USD) exceed its long-term liabilties (13m USD).
APVO has negative Operating Income for the last twelve months.
APVO has negative Net Income for the last twelve months.
APVO's ROE (Return on Equity) for the past 12 months is negative and is equal to -115%.
APVO's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -483%.
APVO's short-term assets (19m USD) exceed its short-term liabilties (7m USD).
APVO has negative Free Cash Flow for the last twelve months.
APVO has negative three-year average ROE (Return on Equity): -209%. The company is not efficient at transforming stockholders' equity into net income.
APVO has negative three-year average ROIC (Return on Invested Capital): -351%. The company is not efficient at using invested capital to generate operating income.
APVO's D/E (Debt to Equity) is very low and is equal to 0.
APVO's Altman Z-Score is very low and is equal to -16.42.
Fundamental Analysis
Aptevo Therapeutics Inc
Balance Sheet Decomposition
Aptevo Therapeutics Inc
| Current Assets | 19.1m |
| Cash & Short-Term Investments | 16.9m |
| Other Current Assets | 2.2m |
| Non-Current Assets | 5.8m |
| PP&E | 5.8m |
| Current Liabilities | 7.2m |
| Accounts Payable | 4m |
| Accrued Liabilities | 2.8m |
| Other Current Liabilities | 442k |
| Non-Current Liabilities | 5.4m |
| Other Non-Current Liabilities | 5.4m |
Earnings Waterfall
Aptevo Therapeutics Inc
|
Revenue
|
0
USD
|
|
Operating Expenses
|
-28.9m
USD
|
|
Operating Income
|
-28.9m
USD
|
|
Other Expenses
|
11.5m
USD
|
|
Net Income
|
-17.4m
USD
|
Free Cash Flow Analysis
Aptevo Therapeutics Inc
APVO Profitability Score
Profitability Due Diligence
Aptevo Therapeutics Inc's profitability score is 19/100. The higher the profitability score, the more profitable the company is.
Score
Aptevo Therapeutics Inc's profitability score is 19/100. The higher the profitability score, the more profitable the company is.
APVO Solvency Score
Solvency Due Diligence
Aptevo Therapeutics Inc's solvency score is 53/100. The higher the solvency score, the more solvent the company is.
Score
Aptevo Therapeutics Inc's solvency score is 53/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
APVO Price Targets Summary
Aptevo Therapeutics Inc
Ownership
APVO Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
APVO Price
Aptevo Therapeutics Inc
| Average Annual Return | 37.69% |
| Standard Deviation of Annual Returns | 186.02% |
| Max Drawdown | -100% |
| Market Capitalization | 459.7k USD |
| Shares Outstanding | 673 430 |
| Percentage of Shares Shorted | 5.12% |
Company Profile
Aptevo Therapeutics Inc
Country
Industry
Market Cap
Dividend Yield
Description
Aptevo Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on developing novel immunotherapies for the treatment of cancer. The company is headquartered in Seattle, Washington and currently employs 54 full-time employees. The company went IPO on 2016-07-20. The firm is focused on developing immunotherapeutic candidates for the treatment of different forms of cancer. The company has developed two platform technologies, such as ADAPTIR and ADAPTIR-FLEX for rational design of precision immune modulatory drugs. Its lead clinical candidate, APVO436, and preclinical candidates, ALG.APV-527 and APVO603, are developed using its ADAPTIR modular protein technology platform. Its preclinical candidate APVO442 is being developed using its ADAPTIR-FLEX modular protein technology platform. APVO436 is a bispecific CD3xCD123 ADAPTIR that is designed to engage CD3 and CD123 to redirect T-cells to destroy leukemia cells expressing the target CD123 molecule on their surface. APVO603 is a preclinical dual agonist bispecific ADAPTIR candidate employing a mechanism of action to simultaneously target 4-1BB (CD137) and OX40 (CD134), both members of the TNF-receptor family.
You don't have any saved screeners yet
